Non-Small Cell Lung Cancer Clinical Trials 2024

Non-Small Cell Lung Cancer Clinical Trials 2024

Non Small Cell Lung Cancer research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in non small cell lung cancer clinical trials today.

Non-Small Cell Lung Cancer Clinical Trials

Here are the 6 most popular medical studies for non-small cell lung cancer

Popular filter options for non-small cell lung cancer trials

Non-Small Cell Lung Cancer Clinical Trials

View 85 Non-Small Cell Lung Cancer medical studies.

NSCLC Clinical Trials

View 85 NSCLC medical studies.

EGFR Positive Clinical Trials

View 13 EGFR positive medical studies.

PD-L1 Positive Clinical Trials

View 11 PD-L1 positive medical studies.

Phase 3 Non Small Cell Lung Cancer Clinical Trials

View 85 phase 3 non small cell lung cancer medical studies.

Non Small Cell Lung Cancer Clinical Trials With No Placebo

View 85 non small cell lung cancer medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to non-small cell lung cancer

What are the top hospitals conducting non-small cell lung cancer research?

When it comes to cutting-edge clinical trials in the battle against non-small cell lung cancer, several top-notch hospitals are leading the charge. In Boston, Massachusetts General Hospital stands out with an impressive 14 ongoing trials dedicated to this disease and a remarkable track record of 115 completed trials since their first recorded study in 2003. Meanwhile, at Dana-Farber Cancer Institute, also located in Boston, researchers are actively engaged in ten current non-small cell lung cancer trials and have contributed to 85 previous studies since their pioneering trial back in 1994.

Not far behind is Memorial Sloan Kettering Cancer Center based in New york City. With eight active non-small cell lung cancer trials and a solid history of conducting 102 prior investigations dating back to their first recorded trial in 2002, they demonstrate unwavering commitment to advancing knowledge and treatment options. Traveling further south brings us to Virginia Cancer Specialists situated in Fairfax. Although smaller-scale than some of its counterparts, this institution plays a significant role with eight ongoing clinical trials for non-small cell lung cancer and has conducted a commendable total of forty-six studies since recording its initial trial back in2010.

Additionally contributing towards these advancements is Princess Margaret Cancer Centre located within Toronto's medical landscape where six current clinical tests specifically focus on cases related to such carcinomas which adds up working hand-in-hand with thirty-two previously held experiments; theirs can be traced back merely eight years ago from2013.

These esteemed hospitals showcase not only dedication but also innovation as they strive tirelessly towards improving treatments for non-small cell lung cancer patients worldwide through groundbreaking research initiatives. Each new discovery or breakthrough brings hope that we are making progress toward more effective therapies for this challenging condition.

Which are the best cities for non-small cell lung cancer clinical trials?

When it comes to non-small cell lung cancer clinical trials, several cities have emerged as leaders in research and development. Boston, Massachusetts boasts the highest number of active trials with 61 ongoing studies focused on investigating treatments like encorafenib, PF-07284890, and Pembrolizumab. New york, New York follows closely behind with 50 active trials exploring various treatment options including PF-07284890, encorafenib, and LY3537982. Los Angeles, California is also a prominent city for clinical trials with 29 ongoing studies investigating treatments such as PF-07284890, Sasanlimab, and Amivantamab. These cities offer individuals battling non-small cell lung cancer access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment outcomes.

Which are the top treatments for non-small cell lung cancer being explored in clinical trials?

Non-small cell lung cancer (NSCLC) research offers a ray of hope through promising treatments currently under exploration in clinical trials. Amivantamab, a relatively new contender introduced in 2016, is making waves with four active trials and 13 all-time NSCLC studies. Osimertinib follows closely behind, having entered the scene in 2015 and now participating in two ongoing trials among its impressive portfolio of 83 all-time NSCLC trials. Additionally, Nivolumab and Pembrolizumab have both made significant strides since their introduction in 2011: each involved in two active NSCLC studies while boasting an incredible record of 122 and 210 all-time clinical trials respectively. With the tireless efforts of researchers, these treatments offer renewed optimism for patients battling non-small cell lung cancer around the world.

What are the most recent clinical trials for non-small cell lung cancer?

Exciting advancements in the field of non-small cell lung cancer (NSCLC) research offer hope for improved treatment options. Prominent among these recent clinical trials is a Phase 2 study focusing on dose expansion, which builds upon the promising results from Phase 1 and Phase 2 trials conducted earlier this year. Additionally, the combination therapy of Amivantamab Plus Lazertinib has shown potential as a background anti-cancer treatment for NSCLC patients. Another trial explores dose escalation strategies in Part 1, aiming to fine-tune treatment approaches through careful evaluation and monitoring. Moreover, an ongoing Phase 3 trial investigates the efficacy of Pembrolizumab combined with Sacituzumab Govitecan. Lastly, another intriguing study focuses on CISH CRISPR TIL in conjunction with PD-L1 inhibitors specifically for NSCLC patients who test positive for PD-L1 expression. These cutting-edge investigations provide encouraging prospects for advancing NSCLC management and improving patient outcomes.

What non-small cell lung cancer clinical trials were recently completed?

Several recently concluded clinical trials have made significant strides in the field of non-small cell lung cancer (NSCLC) research. Notably, Erasca, Inc.'s trial investigating ERAS-007 was completed in September 2021, while EMD Serono Research & Development Institute, Inc.'s M1231 trial concluded in January 2021. Additionally, Cantargia AB's CAN04 trial finished in September 2020 and Gan and Lee Pharmaceuticals' GLR2007 study wrapped up in July 2020. These advancements demonstrate ongoing efforts to advance treatment options for NSCLC patients and highlight the dedication of researchers working towards improved outcomes for this challenging disease.